N
NEUP
Neuphoria Therapeutics Inc
4.600
+0.280+6.48%After Hours: 4.620 +0.020 +0.43%18:30 04/07 EDT
OPEN/PREV CLOSE4.290/4.320
TODAY RANGE4.250-4.600
VOL132.45K
MARKET CAP24.80M
52 WEEK RANGE3.645-21.40
AVG VOL (3M)51.36K
% TURNOVER2.46%
TURNOVER--
P/E (TTM)-2.1693
% RANGE8.33%
EPS(TTM)-2.1205
P/E(FORWARD)-1.1302
P/B0.8328
BVPS5.52
DIVIDEND--
P/S0.5816
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP22.88M
SHARES OUTSTANDING5.39M
NEXT EARNINGS05/18-05/22
FREE FLOAT4.97M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
TipRanks·01/08 11:32
Neuphoria Therapeutics Announces CEO Transition and Consulting Role
TipRanks·12/17/2025 21:39
Neuphoria Therapeutics Shareholders Align on Key Proposals
TipRanks·12/08/2025 13:05
Neuphoria announces ISS recommends shareholders vote ‘FOR’ director nominees
Dow Jones·12/05/2025 13:05
Neuphoria Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones·12/05/2025 13:05
Neuphoria Therapeutics Price Target Cut to $7.00/Share From $21.00 by HC Wainwright & Co.
Benzinga·12/05/2025 12:55
HC Wainwright & Co. Maintains Buy on Neuphoria Therapeutics, Lowers Price Target to $7
TipRanks·12/05/2025 12:50
Analysts Are Bullish on Top Healthcare Stocks: Adicet Bio (ACET), Palvella Therapeutics (PVLA)
TipRanks·12/05/2025 12:45
Neuphoria Therapeutics price target lowered to $7 from $21 at H.C. Wainwright
Reuters·12/05/2025 12:34
NEUPHORIA THERAPEUTICS INC. <NEUP.O>: H.C. WAINWRIGHT CUTS TARGET PRICE TO $7 FROM $21
TipRanks·12/04/2025 13:10
Neuphoria Therapeutics responds to Lynx1’s revised indication of interest
Reuters·12/04/2025 13:00
NEUPHORIA RESPONDS TO LYNX1’S REVISED INDICATION OF INTEREST AT A REDUCED PRICE AND PREMIUM
Same Industry
Name/Symbol
Change%
Price